Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-007 vs dacarbazine in previously untreated metastatic malignant melanoma
2007-004097-32Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- May 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nab-paclitaxel in melanoma (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started May 2009; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-004097-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004097-32.